doi: 10.1161/01.CIR.0000048897.03553.E4
(Circulation. 2003;107:636.)
© 2003 American Heart Association, Inc.
Current Perspectives |
Burgeoning Dilemmas in the Management of Diabetes and Cardiovascular Disease
Rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
From the University of Vermont College of Medicine, Burlington (B.E.S.); Mayo Clinic Foundation, Rochester, Minn (R.F.); and the University of Pittsburgh, Pittsburgh, Pa (K.M.D.).
Correspondence to Burton E. Sobel, MD, Professor and Chair, Department of Medicine, University of Vermont College of Medicine, Colchester Research Facility, 208 So. Park Dr, Colchester, VT 05446. E-mail burt.sobel{at}vtmednet.org
A paradoxical increase in mortality attributable to diabetes has occurred, particularly during the last decade, despite the overall decrease in mortality attributable to coronary artery disease in patients without diabetes. Insulin resistance with or without frank type 2 diabetes has emerged as a major determinant of accelerated coronary artery disease and its sequelae. The advent of insulin sensitizers enables clinicians to target treatment of insulin resistance, as well as hyperglycemia and dyslipidemia. The prevalence of diabetes in the United States is enormous and is increasing rapidly. Patients with diabetes respond less favorably to percutaneous coronary interventions and surgery compared with nondiabetic patients. These considerations led to the initiation of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. It is designed to determine whether treatment targeted to attenuate insulin resistance can arrest or retard progression of coronary artery disease compared with treatment targeted to the same level of glycemic control with an insulin-providing approach. It is designed also to determine whether early revascularization reduces mortality and morbidity in patients with type 2 diabetes whose cardiac symptoms are mild and stable. Despite challenges in study design and enrollment, intensive follow-up, and the long duration of follow-up planned, the questions being addressed are compelling and seem to merit the effort.
Key Words: diabetes mellitus • angioplasty • revascularization • cardiovascular diseases
This article has been cited by other articles:
 |
|
 |
|
  D.-W. Park, S.-C. Yun, S.-W. Lee, Y.-H. Kim, C. W. Lee, M.-K. Hong, J.-J. Kim, S. J. Choo, H. Song, C. H. Chung, et al. Long-Term Mortality After Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Artery Disease Circulation, April 22, 2008; 117(16): 2079 - 2086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Th. Wackers, D. A. Chyun, L. H. Young, G. V. Heller, A. E. Iskandrian, J. A. Davey, E. J. Barrett, R. Taillefer, S. D. Wittlin, N. Filipchuk, et al. Resolution of Asymptomatic Myocardial Ischemia in Patients With Type 2 Diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study Diabetes Care, November 1, 2007; 30(11): 2892 - 2898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Erdmann Review: Statin plus thiazolidinedione use in patients with diabetes at high cardiovascular risk The British Journal of Diabetes & Vascular Disease, September 1, 2007; 7(5): 211 - 216. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Hollander, D. Yu, and H. S. Chou Low-Dose Rosiglitazone in Patients With Insulin-Requiring Type 2 Diabetes Arch Intern Med, June 25, 2007; 167(12): 1284 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Singh, C. S. Rihal, B. J. Gersh, R. J. Lennon, A. Prasad, P. Sorajja, R. E. Gullerud, and D. R. Holmes Jr Twenty-Five-Year Trends in In-Hospital and Long-Term Outcome After Percutaneous Coronary Intervention: A Single-Institution Experience Circulation, June 5, 2007; 115(22): 2835 - 2841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Gavin III An Uncompromising Approach to Achieving Glycemic Goals The Diabetes Educator, March 1, 2007; 33(Supplement_3): 52S - 59S. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Berry, J.-C. Tardif, and M. G. Bourassa Coronary Heart Disease in Patients With Diabetes: Part II: Recent Advances in Coronary Revascularization J. Am. Coll. Cardiol., February 13, 2007; 49(6): 643 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Berry, J.-C. Tardif, and M. G. Bourassa Coronary Heart Disease in Patients With Diabetes: Part I: Recent Advances in Prevention and Noninvasive Management J. Am. Coll. Cardiol., February 13, 2007; 49(6): 631 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Scognamiglio Reply J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1917 - 1917. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Breeman, M. Hordijk-Trion, M. Lenzen, S. Hoeks, J. P. Ottervanger, M. E. Bertrand, U. Sechtem, R. Zaliunas, V. Legrand, M.-J. de Boer, et al. Treatment decisions in stable coronary artery disease: insights from the Euro Heart Survey on Coronary Revascularization. J. Thorac. Cardiovasc. Surg., November 1, 2006; 132(5): 1001 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Breeman, M. E. Bertrand, J. P. Ottervanger, S. Hoeks, M. Lenzen, U. Sechtem, V. Legrand, M.-J. de Boer, W. Wijns, E. Boersma, et al. Diabetes does not influence treatment decisions regarding revascularization in patients with stable coronary artery disease. Diabetes Care, September 1, 2006; 29(9): 2003 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Soares, W. A. Hueb, P. A. Lemos, N. Lopes, E. E. Martinez, L. A.M. Cesar, S. A. Oliveira, and J. A.F. Ramires Coronary Revascularization (Surgical or Percutaneous) Decreases Mortality After the First Year in Diabetic Subjects but not in Nondiabetic Subjects With Multivessel Disease: An Analysis From the Medicine, Angioplasty, or Surgery Study (MASS II) Circulation, July 4, 2006; 114(1_suppl): I-420 - I-424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Williams Coronary Revascularization in Diabetic Chronic Kidney Disease/End-Stage Renal Disease: A Nephrologist's Perspective Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 209 - 220. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kendall Thiazolidinediones: The case for early use Diabetes Care, January 1, 2006; 29(1): 154 - 157. [Full Text] [PDF]
|
|
|
|
|
|
S. B. King III Angioplasty Is Better Than Medical Therapy for Alleviating Chronic Angina Pectoris Arch Intern Med, December 12, 2005; 165(22): 2589 - 2592. [Full Text] [PDF]
|
|
|
|
|
|
S. B. King III, G. Dangas, J. W. Moses, S. B. King III, G. Dangas, and J. W. Moses Surgery Is Preferred for the Diabetic With Multivessel Disease Circulation, September 6, 2005; 112(10): 1500 - 1515. [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Salmasi and M. Dancy The Glucose Tolerance Test, But Not HbA 1c, Remains the Gold Standard in Identifying Unrecognized Diabetes Mellitus and Impaired Glucose Tolerance in Hypertensive Subjects Angiology, September 1, 2005; 56(5): 571 - 579. [Abstract] [PDF]
|
|
|
|
|
|
P. Sorajja, P. Chareonthaitawee, N. Rajagopalan, T. D. Miller, R. L. Frye, D. O. Hodge, and R. J. Gibbons Improved Survival in Asymptomatic Diabetic Patients With High-Risk Spect Imaging Treated With Coronary Artery Bypass Grafting Circulation, August 30, 2005; 112(9_suppl): I-311 - I-316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Cordeiro da Rocha, N. P. Rodrigues Dassa, F. J. Monassa Pittella, O. N. Barbosa, J. O. Reis Brito, B. Tura, and P. R. Dutra da Silva High Mortality Associated With Precluded Coronary Artery Bypass Surgery Caused by Severe Distal Coronary Artery Disease Circulation, August 30, 2005; 112(9_suppl): I-328 - I-331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Second World Congress on the Insulin Resistance Syndrome: Hypertension, cardiovascular disease, and treatment approaches Diabetes Care, August 1, 2005; 28(8): 2073 - 2080. [Full Text] [PDF]
|
|
|
|
|
|
R. B. Goldberg, D. M. Kendall, M. A. Deeg, J. B. Buse, A. J. Zagar, J. A. Pinaire, M. H. Tan, M. A. Khan, A. T. Perez, S. J. Jacober, et al. A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia Diabetes Care, July 1, 2005; 28(7): 1547 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patel, K. L Wyne, and D. K McGuire Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diabetes and Vascular Disease Research, May 1, 2005; 2(2): 61 - 66. [Abstract] [PDF]
|
|
|
|
 |
|
 J. D. Flaherty and C. J. Davidson Diabetes and Coronary Revascularization JAMA, March 23, 2005; 293(12): 1501 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mehilli, A. Kastrati, H. Schuhlen, A. Dibra, F. Dotzer, N. von Beckerath, H. Bollwein, J. Pache, J. Dirschinger, P. P. Berger, et al. Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel Circulation, December 14, 2004; 110(24): 3627 - 3635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Skyler Effects of Glycemic Control on Diabetes Complications and on the Prevention of Diabetes Clin. Diabetes, October 1, 2004; 22(4): 162 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Leavitt, L. Sheppard, C. Maloney, R. A. Clough, J. H. Braxton, D. C. Charlesworth, R. M. Weintraub, F. Hernandez, E. M. Olmstead, W. C. Nugent, et al. Effect of Diabetes and Associated Conditions on Long-Term Survival After Coronary Artery Bypass Graft Surgery Circulation, September 14, 2004; 110(11_suppl_1): II-41 - II-44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fradkin Diabetes Clinical Trials: What Is New at NIDDK? Clin. Diabetes, July 1, 2004; 22(3): 109 - 112. [Full Text] [PDF]
|
|
|
|
 |
|
 C Casey and D. P Faxon Multi-vessel coronary disease and percutaneous coronary intervention Heart, March 1, 2004; 90(3): 341 - 346. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Roffi and E. J. Topol Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes Eur. Heart J., February 1, 2004; 25(3): 190 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Sobel Coronary Disease in Type 1 Diabetes: Causal contiguity and clinical implications Diabetes Care, May 1, 2003; 26(5): 1629 - 1630. [Full Text] [PDF]
|
|